Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of KAKEN PHARMACEUTICAL CO., LTD.. A complete text table follows the diagram.
License revenue fell JPY13.9B and R&D nearly doubled to JPY11.7B as Kaken acquired rights to three pipeline programs.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Real estate | 1 | 682M | 100.0% of reported total |
| Gross operating income | 2 | 682M | Reported six-month total · ¥682M |
| Operating income | 3 | 203M | Reported consolidated total |
| Pharmaceutical operating loss | 3 | 479M | Reported negative segment contribution |
| From | To | Value |
|---|---|---|
| Real estate | Gross operating income | 682M |
| Gross operating income | Operating income | 203M |
| Gross operating income | Pharmaceutical operating loss | 479M |